ReviewDrugs2007
Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02437851 (A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Imiquimod for anogenital warts in non-immunocompromised adults.The Cochrane database of systematic reviews · 2014Pooled it
- Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers.Clinical and translational science · 2020Trial
- Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod.Journal of the American Academy of Dermatology · 2012Trial
- The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2012Trial
- Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia.American journal of obstetrics and gynecology · 2012Trial
- Topical Imiquimod for Oral Cavity Leukoplakia and Dysplasia: A Scoping Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Skin-Directed Therapies in Mycosis Fungoides: An Update.Dermatology and therapy · 2025Review
- Involvement of nucleic acid-sensing toll-like receptors in human diseases and their controlling mechanisms.Journal of biomedical science · 2025Review
- Conglomerated Imiquimod and Metronidazole Incorporated Biodegradable Nanofibrous Mats for Potential Therapy of Cervical Cancer.International journal of nanomedicine · 2025Article
- Intratumoral sustained release of resiquimod with ablative fractional laser induces efficacy in a cutaneous squamous cell carcinoma mouse model.Frontiers in immunology · 2025Article
- Non-surgical management of recurrent Paget's disease of the vulva: A case report.Gynecologic oncology reports · 2024Article
- Article
- Article
- Emerging adjuvants for intradermal vaccination.International journal of pharmaceutics · 2023Review
- Development of Optimal Virtual Screening Strategies to Identify Novel Toll-Like Receptor Ligands Using the DockBox Suite.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Presence of TRPA1 Modifies CD4+/CD8+ T Lymphocyte Ratio and Activation.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases.Cells · 2021Review
- Review
- A case report of imiquimod topical therapy as treatment for cutaneous metastasis of breast cancer.Rare tumors · 2021Article
- Co-Delivery of Imiquimod and Curcumin by Nanoemugel for Improved Topical Delivery and Reduced Psoriasis-Like Skin Lesions.Biomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical imiquimod 5% cream (Aldara) is an immune response modulator that is indicated for the treatment of external anogenital warts, superficial basal cell carcinoma and actinic keratoses. The cream is applied two to five times per week for varying periods, depending on the indication. Topical imiquimod cream has also been evaluated in the treatment of several other skin conditions. Immunomodulatory therapy with topical imiquimod 5% is an effective option for the approved indications. The drug appears to be relatively well tolerated, with the option of breaks from treatment as required for local skin reactions (which are common). Systemic reactions have been reported. Treatment of human papillomavirus- and UV-associated skin lesions with topical imiquimod offers a noninvasive, tissue-sparing alternative to ablative treatment options. However, well designed trials of the sustained, long-term efficacy and tolerability of topical imiquimod versus those of common treatment approaches including surgery and other topical alternatives are required before the place of the drug in the management of these lesions can be finalised. Nonetheless, while other treatments for anogenital warts, superficial basal cell carcinoma or actinic keratoses are available, the advantages of self treatment linked with the demonstrated efficacy of topical imiquimod offer an attractive alternative for many patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.